
ECP Growth Companies Fund



Fund report | October 2025

Capital growth vs income.....



Mid cap bias.....



Investment style



Key facts

Investment strategy
A high conviction, Australian equities
portfolio designed to deliver alpha
above benchmark

Investment objective Outperform index by over 2-4% p.a. over 5 years

Benchmark index S&P/ASX 300 Accumulation Index

Fund Manager ECP Asset Management

Inception date
Jan 2020 (strategy commenced 2012)

Management fee 0.90% p.a.¹

Performance fee 15.375% of benchmark outperformance¹

Number of stocks Typically 25-30

Ratings

Lonsec Highly Recommended Zenith Recommended Lonsec 5 Bees Sustainability Score

Platforms


BT Panorama, Netwealth, Powerwrap, Praemium, Hub24, Macquarie, North, Mason Stevens, CFS

Performance*

At month end	1 mth	3 mth	6 mth	1 yr	3 yr	5yr	Incep.+
ECP Growth Companies Fund	-2.4%	-2.7%	5.1%	-3.3%	11.6%	6.0%	11.6%
S&P/ASX 300 Accumulation Index	0.4%	2.9%	11.4%	12.7%	13.0%	12.5%	10.1%
Outperformance	-2.9%	-5.6%	-6.3%	-16.0%	-1.4%	-6.5%	1.5%

*(%, returns greater than one year are per annum) | 'Inception of the ECP Growth Companies Fund for performance calculation purposes is 31 July 2012 (based on the underlying strategy ECPAM All Cap strategy returns).

Performance comparison of \$10,000 since inception



Monthly commentary.....

HUB24 (HUB) outperformed during October as its periodic business updates continued to exhibit material net inflows to its wealth platform, a continuation of its market share gains. Sentiment toward HUB has been boosted recently, with the probability of a stronger flow pipeline rising on the back of various competitor-platform headlines that've been frequented in the media of late. With attractive margins and operating leverage incrementally flowing through, the outlook remains compelling for HUB.

James Hardie Industries (JHX) was a key outperformer in October as the stock rebounded from its recent lows following a 2Q trading update that signaled stabilizing market conditions. While the underlying housing and Repair & Remodel (R&R) markets remain soft, the acute destocking headwind has abated, and sales volumes have normalized. We remain constructive on JHX, viewing it as the premier pure-play operator in North American building materials. Its dominant siding franchise, combined with strategic expansion into complementary categories, positions the company for strong medium-term earnings growth.

WiseTech (WTC) underperformed in October as the share price continues its slip post a mixed FY25 result (a key product delay, 2H25 deceleration with a further 1H26 implied slowdown, before later reaccelerating), and headlines regarding its Executive Chairman & Founder being investigated for possible insider trading. Our long-term thesis remains unchanged, and we believe significant growth is ahead from existing customer rollouts, product penetration, new product development, and major new customer wins. Our investment thesis is not tied to founder White, where we believe the company's competitive position has matured past the need for any one key person.

IDP Education (IEL) underperformed in October following its AGM. Guidance for FY26 remained unchanged, leading investors to question whether a recent pick-up in IELTS web traffic is a genuine early indicator of recovery in student sentiment towards IDP's major destination markets. We believe it is still too early to forecast a recovery; however, IDP's ongoing cost-out program will deliver material margin improvements from the cyclical low point in FY25, and will deliver higher incremental margins in the longer term as volumes recover.


Sector allocation

GICS sector	ECP %	Index %	+/- %
Communication Services	9.79	3.85	5.94
Consumer Discretionary	22.03	7.59	14.43
Consumer Staples	0.00	3.42	-3.42
Energy	0.00	3.64	-3.64
Financials	20.36	33.57	-13.21
Health Care	18.27	7.51	10.76
Industrials	2.85	7.63	-4.78
Information Technology	18.41	3.45	14.96
Materials	5.89	21.08	-15.20
Real Estate	0.00	6.83	-6.83
Utilities	0.00	1.39	-1.39
Cash	2.42	0.04	2.38
Total	100.0%	100.0%	-

Why ECP?

















Top 10 holdings

Company	Weight %
ResMed Inc	6.34
Block Inc	6.25
Judo Capital Holdings Ltd	5.04
Guzman y Gomez Ltd	4.80
Xero Ltd	4.63
IDP Education	4.62
James Hardie Industries	4.11
Corporate Travel Management Ltd	4.10
CSL Ltd	4.02
Cochlear Ltd	3.99

Key contributors

Company	Weight %
James Hardie Industries	4.05
HUB24 Ltd	3.64
PWR Holdings Ltd	2.93

Key detractors

Company	Weight %
WiseTech Global Ltd	3.81
IDP Education Ltd	5.04
Nuix Ltd	2.95

Portfolio metrics (5yr)

Portfolio IRR	15.10
Beta (5Y)	1.12
Downside Capture (5Y)	1.00

1800 442 129

clientservices@copiapartners.com.au

www.copiapartners.com.au

For further information, please contact our distribution partner, Copia Investment Partners



1 inclusive of GST, net of RITC Disclaimer: The total return performance figures quoted are historical, calculated using hard close, end-of-month mid-prices and do not allow for the effects of income tax or inflation. Total returns assume the reinvestment of all distributions. The performance is quoted net of all fees and expenses. The index does not incur these costs. This information is provided for general comparative purposes. Past performance is not a reliable indicator of future performance. Positive returns, which the ECP Growth Companies Fund (the Fund) is designed to provide, are different regarding risk and investment profile to index returns. This document is for general information purposes only and does not take into account the specific investment objectives, financial situation or particular needs of any specific individual. As such, before acting on any information contained in this document, individuals should consider whether the information is suitable for their needs. This may involve seeking advice from a qualified financial adviser. Copia Investment Partners Ltd (AFSL 229316, ABN 22 092 872 056) (Copia) is the issuer of the ECP Growth Companies Fund. A current PDS is available from ecpam.com. A person should consider the PDS before deciding whether to acquire or continue to hold an interest in the Fund. Any opinions or recommendations contained in this document are subject to change without notice and Copia is under no obligation to update or keep any information contained in this document current. The rating issued October 2025 APIR OPS2991AU is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec. com.au for ratings information and to access the full report. © 2024 Lonsec. All rights reserved. The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned APIR OPS2991AU June 2025) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at http://www.zenithpartners.com.au/RegulatoryGuidelines